Elisabetta Di Leo Selected Research

Elisabetta Di Leo Research Topics

Disease

11	Hypersensitivity (Allergy) 01/2020 - 01/2008
8	Chronic Urticaria 01/2019 - 01/2010
6	Atopic Dermatitis (Atopic Eczema) 05/2022 - 01/2010
6	Urticaria (Hives) 01/2020 - 01/2008
4	Asthma (Bronchial Asthma) 05/2022 - 10/2020
3	Rhinosinusitis 05/2022 - 03/2021
3	Nasal Polyps (Nasal Polyp) 05/2022 - 03/2021
3	Angioedema 12/2021 - 01/2008
2	Anaphylaxis (Anaphylactic Shock) 11/2020 - 01/2019
2	Exanthema (Rash) 01/2019 - 02/2013
2	Stevens-Johnson Syndrome (Lyell's Syndrome) 01/2016 - 02/2013
2	Drug Hypersensitivity (Drug Allergy) 01/2016 - 07/2011
1	Mastocytosis 12/2021
1	Hereditary Angioedemas 12/2021
1	Allergic Rhinitis 06/2021
1	Conjunctivitis 06/2021
1	Measles 11/2020
1	Egg Hypersensitivity (Egg Allergy) 11/2020
1	Rubella (German Measles) 11/2020
1	Mumps 11/2020
1	Eczema 10/2020
1	Pruritus (Itching) 10/2020
1	Rhinitis 10/2020
1	Ectropion 01/2020
1	Eosinophilia 01/2019
1	Melkersson-Rosenthal Syndrome 07/2018
1	Contact Dermatitis (Eczema, Contact) 01/2017
1	Erythema Multiforme 01/2016
1	Exfoliative Dermatitis (Erythroderma) 01/2016
1	Urinary Retention 09/2013
1	Cold Urticaria 09/2013
1	Headache (Headaches) 09/2013
1	Fatigue 09/2013
1	Erectile Dysfunction 09/2013
1	Dry Eye Syndromes (Dry Eye Syndrome) 09/2013
1	Constipation 09/2013
1	Sleepiness 09/2013
1	Drug Eruptions (Drug Eruption) 02/2013
1	Gout 02/2013
1	Hyperuricemia 02/2013
1	Latex Hypersensitivity (Latex Allergy) 09/2012
1	Glaucoma 01/2011
1	Lymphoma (Lymphomas) 01/2011
1	Postoperative Pain 01/2008

Drug/Important Bio-Agent (IBA)

8	Omalizumab (Xolair)FDA Link 01/2020 - 01/2018
5	dupilumabIBA 05/2022 - 01/2020
5	Pharmaceutical PreparationsIBA 01/2020 - 01/2008
3	AllergensIBA 11/2020 - 01/2014
3	LatexIBA 01/2019 - 08/2010
2	Immunoglobulin E (IgE)IBA 10/2020 - 10/2018
2	anti-IgE antibodiesIBA 01/2020 - 01/2019
2	Histamine Antagonists (Antihistamines)IBA 04/2018 - 01/2018
1	BradykininIBA 12/2021
1	Dipeptidyl-Peptidase IV InhibitorsIBA 12/2021
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 12/2021
1	EnzymesIBA 12/2021
1	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 12/2021
1	Measles-Mumps-Rubella Vaccine (MMR Vaccine)IBA 11/2020
1	Attenuated VaccinesIBA 11/2020
1	Rubella VaccineIBA 11/2020
1	ThienopyridinesIBA 01/2020
1	myasthenia gravis anti-skeletal muscle antibody (ASMA)IBA 01/2020
1	Contrast MediaIBA 01/2020
1	Clopidogrel (Plavix)FDA Link 01/2020
1	thienopyridineIBA 01/2020
1	ImidazolesIBA 01/2019
1	Voriconazole (Vfend)FDA LinkGeneric 01/2019
1	Ketoconazole (Nizoral)FDA LinkGeneric 01/2019
1	AzolesIBA 01/2019
1	Antifungal AgentsIBA 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	Fluconazole (Zonal)FDA LinkGeneric 01/2019
1	Itraconazole (Sporanox)FDA LinkGeneric 01/2019
1	EstersIBA 01/2019
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019
1	Excipients (Suspending Agents)IBA 01/2019
1	Succinic Acid (Succinate)IBA 01/2019
1	posaconazole FDA Link 01/2019
1	TriazolesIBA 01/2019
1	4-phenylenediamine (p-phenylenediamine)FDA Link 01/2017
1	Tuberculin (PPD)IBA 01/2017
1	rupatadineIBA 09/2013
1	HypoxanthineIBA 02/2013
1	Allopurinol (Remid)FDA LinkGeneric 02/2013
1	GlucocorticoidsIBA 07/2011
1	Tranexamic Acid (AMCA)FDA Link 08/2010
1	montelukast (Singulair)FDA Link 01/2010
1	zileuton (Zyflo)FDA Link 01/2010
1	zafirlukast (Accolate)FDA LinkGeneric 01/2010
1	Analgesics (Analgesic Drugs)IBA 01/2008

Therapy/Procedure

3	Therapeutics 01/2020 - 01/2011
1	Biological Therapy 12/2021
1	Premedication 01/2020
1	Stents 01/2020
1	Retreatment 06/2018
1	Tattooing 01/2017
1	Immunotherapy 09/2012
1	Vitrectomy 01/2011
1	Trabeculectomy (Trabeculoplasty) 01/2011
1	Injections 01/2008